Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

Neurology

Volumn 70, Issue 8, 2008, Pages 607-616

  Noachtar, S ^a   Andermann, E ^b,c   Meyvisch, P ^d   Andermann, F ^b,c   Gough, W B ^e   Schiemann Delgado, J ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UCB PHARMA   (Belgium)

^e Insight Medical Communications Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; PLACEBO;

ABSENCE; ADULT; AGE DISTRIBUTION; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERALIZED EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NECK PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 39749166363     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000297512.18364.40     Document Type: Article

References (43)

1. International League Against Epilepsy. Commission on Classification and Terminology. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
2. Janz D, Durner M. Juvenile myoclonic epilepsy. In: Engel J Jr., Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers, 1997:2389-2400.
3. Zifkin B, Andermann E, Andermann F. Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. Curr Opin Neurol 2005;18:147-153.
4. Mattson RH. Overview: idiopathic generalized epilepsies. Epilepsia 2003;44:Suppl 2:2-6.
5. Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003;79:78-80.
6. Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340:1565-1570.
7. Shinnar S, Berg AT, Moshe SL, et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol 1994;35:534-545.
8. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-1109.
9. Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003;44:Suppl 2:27-32.
10. Obeso JA, Artieda J, Quinn N, et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11:529-536.
11. Ikeda A, Shibasaki H, Tashiro K, et al. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996;11:691-700.
12. Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998;64:344-348.
13. Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58:781-786.
14. Agakhani Y, Andermann F, Andermann E. Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy. Epilepsia 2005;46:1145-1146.
15. Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy. An exploratory study in 9 patients. Neurology 2004;62:640-643.
16. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-1114.
17. Genton P, Gélisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000;2:209-212.
18. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004;45:678-681.
19. Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003;12:617-620.
20. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 2004;13:475-477.
21. Betts T, Greenhill L, Yarrow H. Effect of levetiracetam on resistant juvenile myoclonic epilepsy [Abstract]. J Neurol 2002;249 suppl 1:132.
22. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, on behalf of the Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-1760.
23. International League Against Epilepsy. Commission on classification and terminology. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
24. Cramer J, Arrigo C, Van Hammée G. Patient-rated priorities and relationship to distress in health-related quality of life domains: the QoLIE-31-P and QoLIE-10-P in a long-term levetiracetam study. Epilepsia 2002;43 suppl 8:1-227.
25. Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 1998;39:81-88.
26. Smith K, Betts T, Pritchett L. Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy [abstract]. Epilepsia 2000;41 suppl:39.
27. Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15:214-218.
28. French J, di Nivola S, Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 2005;46:1304-1307.
29. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-1660.
30. Cramer JA, Arrigo C, Van Hammee G, et al. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 2000;41:868-874.
31. Sundqvist A, Tomson T, Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit 1998;20:149-157.
32. Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737-1743.
33. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-372.
34. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004;45:1171-1175.
35. Sullivan JE, Dlugos DJ. Idiopathic generalized epilepsy. Curr Treat Options Neurol 2004;6:231-242.
36. Perucca E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monit 2002;24:74-80.
37. Wheless JW, Bourgeois BF. Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders. J Child Neurol 2004;19 suppl 1:S39-S48.
38. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
39. Shorvon SD, Löwenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186.
40. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-1283.
41. Boon P, Chauvel P, Pohlmann-Eden B, et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002;48:77-89.
42. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001;47:77-90.
43. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-724.